4 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
Follow Bone Diseases, Infectious: new trials by email Literature Review of Bone Diseases, Infectious trials Research Report on Bone Diseases, Infectious
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis Bacteriophage Therapy, Placebo - Osteomyelitis, Diabetic Foot Osteomyelitis | Phase 2 | Terminated | Adaptive Phage Therapeutics, Inc. | 41 | 2021-11-24 | 2025-08-19 |
| Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials Celecoxib, Naproxen, Meloxicam - Axial Spondyloarthritis | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 42 | 2020-06-25 | 2025-08-13 |
| Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Dalbavancin, Standard of Care - Osteomyelitis | Phase 2 | Terminated | Allergan | 1 | 2017-05-15 | 2018-09-26 |
| Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis Intravenous Antibacterial Agent, Oral Antibacterial Agent - Osteomyelitis | Phase 2 | Terminated | Loyola University | 30 | 2014-03-19 | 2018-07-19 |
Osteomyelitis (3) · Diabetes Mellitus (2) · Axial Spondyloarthritis (1) · Spondylitis (1)
Bone Diseases (4) · Infections (4) · Musculoskeletal Diseases (4) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Ankylosis (1) · Arthritis (1) · Joint Diseases (1) · Spinal Diseases (1) · Spondylarthritis (1) · Spondylarthropathies (1)
Anti-Bacterial Agents (1) · Aztreonam (1) · Cefepime (1) · Celecoxib (1) · Ciprofloxacin (1) · Clindamycin (1) · Daptomycin (1) · Linezolid (1) · Meloxicam (1) · Meropenem (1) · Metronidazole (1) · Moxifloxacin (1) · Naproxen (1) · Phage Therapy (1) · Piperacillin (1)
Adaptive Phage Therapeutics, Inc. (1) · Allergan (1) · Loyola University (1) · The University of Texas Health Science Center, Houston (1)
United States (4)
Mark C Hwang, MD (1) · Michael Pinzur, M.D. (1) · Nitsan Halevy, MD (1) · Urania Rappo, MD (1)
KL2TR003168 (1)